1. Home
  2. AUPH vs BLMN Comparison

AUPH vs BLMN Comparison

Compare AUPH & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • BLMN
  • Stock Information
  • Founded
  • AUPH 1993
  • BLMN 1988
  • Country
  • AUPH Canada
  • BLMN United States
  • Employees
  • AUPH N/A
  • BLMN N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • BLMN Restaurants
  • Sector
  • AUPH Health Care
  • BLMN Consumer Discretionary
  • Exchange
  • AUPH Nasdaq
  • BLMN Nasdaq
  • Market Cap
  • AUPH 1.1B
  • BLMN 736.6M
  • IPO Year
  • AUPH 1999
  • BLMN 2012
  • Fundamental
  • Price
  • AUPH $8.86
  • BLMN $10.03
  • Analyst Decision
  • AUPH Strong Buy
  • BLMN Hold
  • Analyst Count
  • AUPH 2
  • BLMN 11
  • Target Price
  • AUPH $11.50
  • BLMN $13.35
  • AVG Volume (30 Days)
  • AUPH 2.0M
  • BLMN 2.7M
  • Earning Date
  • AUPH 07-31-2025
  • BLMN 08-05-2025
  • Dividend Yield
  • AUPH N/A
  • BLMN 5.90%
  • EPS Growth
  • AUPH N/A
  • BLMN N/A
  • EPS
  • AUPH 0.27
  • BLMN N/A
  • Revenue
  • AUPH $247,295,000.00
  • BLMN $3,930,996,000.00
  • Revenue This Year
  • AUPH $12.15
  • BLMN $1.28
  • Revenue Next Year
  • AUPH $18.31
  • BLMN $1.55
  • P/E Ratio
  • AUPH $33.08
  • BLMN $11.10
  • Revenue Growth
  • AUPH 29.20
  • BLMN N/A
  • 52 Week Low
  • AUPH $5.20
  • BLMN $6.09
  • 52 Week High
  • AUPH $10.67
  • BLMN $21.45
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 64.10
  • BLMN 60.41
  • Support Level
  • AUPH $7.36
  • BLMN $9.49
  • Resistance Level
  • AUPH $9.10
  • BLMN $10.28
  • Average True Range (ATR)
  • AUPH 0.44
  • BLMN 0.55
  • MACD
  • AUPH 0.10
  • BLMN 0.06
  • Stochastic Oscillator
  • AUPH 89.53
  • BLMN 86.19

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.

Share on Social Networks: